Investor Alert: Bronstein, Gewirtz & Grossman LLC reports on Organon …

A class action lawsuit has been initiated against Organon & Co. (“Organon” or “the Company”) (NYSE: OGN) and some of its officers. The lawsuit involves a class of individuals who purchased or otherwise acquired Organon securities between August 12, 2021, and October 29, 2021 (the “Class Period”). The lawsuit alleges that Organon and certain of its officers made false and misleading statements regarding the Company’s business, operational, and compliance policies.

According to the lawsuit, Organon misrepresented the commercial prospects of its product, EluRyng. The Company allegedly misled investors by failing to disclose the negative impact of increased competition on EluRyng’s sales and revenues. Organon is accused of misleading investors to believe that EluRyng’s commercial prospects were much more promising than they actually were.

Moreover, the lawsuit claims that Organon failed to disclose its reliance on a risky “rebate-like” strategy to drive EluRyng sales. This strategy reportedly resulted in significant financial risks that were not adequately disclosed to investors. The lawsuit alleges that Organon’s failure to disclose these risks misled investors about the Company’s financial condition and prospects.

Organon’s alleged misrepresentations and omissions supposedly caused the Company’s stock price to trade at artificially inflated levels during the Class Period. Once the truth about EluRyng’s commercial prospects and the risks associated with Organon’s sales strategy were revealed, the Company’s stock price reportedly dropped significantly. This drop allegedly caused financial harm to investors who purchased Organon securities during the Class Period.

The lawsuit seeks to recover damages on behalf of the class of investors who were allegedly harmed by Organon’s alleged misconduct. If you purchased or otherwise acquired Organon securities between August 12, 2021, and October 29, 2021, you may be a member of the class action lawsuit. To participate in the lawsuit, you must meet the class definition criteria as outlined in the lawsuit filing.

In conclusion, the class action lawsuit against Organon & Co. alleges that the Company and certain officers made false and misleading statements about its business and prospects. The lawsuit claims that Organon misrepresented the commercial prospects of its product, EluRyng, and failed to disclose significant financial risks associated with its sales strategy. Investors who purchased Organon securities during the Class Period may be eligible to participate in the lawsuit and seek damages for any alleged financial harm incurred as a result of Organon’s alleged misconduct.